Alexandra Phillips
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Phillips has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Rajeshwar Prosad Mookerjee
Liver Failure Group UCL Institute for Liver and Digestive Health London UK
2 shared publications Aarti Jalan
Kings College Hospital London UK
1 shared publicationAbeba Habtesion
Liver Failure Group UCL Institute for Liver and Digestive Health London UK
1 shared publicationAdria Juanola
Liver Unit, IDIBAPS, CIBEReHD, Faculty of Medicine and Health Sciences, Hospital Clinic of Barcelona University of Barcelona Barcelona Spain
1 shared publication- Agustín Albillos
Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
1 shared publication - Ainhoa Ferret-Miñana
Institute for Bioengineering of Catalonia (IBEC) Barcelona Spain
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70933
Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis
Background & Aims: YAQ001 is a novel, non‐absorbable, gut‐restricted, multiporous, carbon bead adsorbent. Pre‐clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with biomarkers of gut permeability and systemic inflammation. Methods: Twenty‐eight‐patients with cirrhosis were randomized (double‐blind) to receive YAQ001 (4 g once daily) or placebo. Gut microbiome and biomarkers of inflammation and gut permeability were assessed at baseline, after 4 and 12 weeks. Changes in biomarkers and relationship with microbiome composition and gene profiling were assessed. The effect of YAQ001 on Klebsiella pneumoniae biofilms was assessed in vitro. Results: Overall alpha and beta diversity remained unaltered. YAQ001 increased the abundance of bacteria associated with improved gut health such as Adlercreutzia equolifaciens , a bacterium commonly depleted in liver disease, and decreased the abundance of bacteria associated with infections and poor outcomes such as Klebsiella pneumonia , and Streptococcus mutans . YAQ001 impacted positively on virulence factors such as siderophores, fimbriae structures, and lipopolysaccharides that are associated with inflammation and invasion. Antibiotic resistance genes decreased significantly in the YAQ001 group. These changes were associated with a reduction in markers of gut permeability and systemic inflammation. YAQ001 prevented K. pneumoniae biofilms in vitro. Conclusion: YAQ001 was associated with favourable compositional shifts and trends towards reduced virulence‐related gene signatures in the gut microbiome, alongside trends towards improved inflammatory biomarkers. The in vitro anti‐biofilm effect of YAQ001 warrants further mechanistic investigation. The findings position YAQ001 as a potential microbiome therapeutic.
- 21 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70933
Open AccessImpact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis
Background & Aims: YAQ001 is a novel, non‐absorbable, gut‐restricted, multiporous, carbon bead adsorbent. Pre‐clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with biomarkers of gut permeability and systemic inflammation. Methods: Twenty‐eight‐patients with cirrhosis were randomized (double‐blind) to receive YAQ001 (4 g once daily) or placebo. Gut microbiome and biomarkers of inflammation and gut permeability were assessed at baseline, after 4 and 12 weeks. Changes in biomarkers and relationship with microbiome composition and gene profiling were assessed. The effect of YAQ001 on Klebsiella pneumoniae biofilms was assessed in vitro. Results: Overall alpha and beta diversity remained unaltered. YAQ001 increased the abundance of bacteria associated with improved gut health such as Adlercreutzia equolifaciens , a bacterium commonly depleted in liver disease, and decreased the abundance of bacteria associated with infections and poor outcomes such as Klebsiella pneumonia , and Streptococcus mutans . YAQ001 impacted positively on virulence factors such as siderophores, fimbriae structures, and lipopolysaccharides that are associated with inflammation and invasion. Antibiotic resistance genes decreased significantly in the YAQ001 group. These changes were associated with a reduction in markers of gut permeability and systemic inflammation. YAQ001 prevented K. pneumoniae biofilms in vitro. Conclusion: YAQ001 was associated with favourable compositional shifts and trends towards reduced virulence‐related gene signatures in the gut microbiome, alongside trends towards improved inflammatory biomarkers. The in vitro anti‐biofilm effect of YAQ001 warrants further mechanistic investigation. The findings position YAQ001 as a potential microbiome therapeutic.
- 8 September 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (1) , 123-132
Evaluation of CirrhoCare® – a digital health solution for home management of individuals with cirrhosis
- 8 September 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (1) , 123-132
Evaluation of CirrhoCare® – a digital health solution for home management of individuals with cirrhosis
- Open Access
- 16 December 2021
- Published by The Ohio State University Libraries
Does Gestalt hearing exist?
- 16 December 2021
- Published by The Ohio State University Libraries
Open AccessDoes Gestalt hearing exist?